Pancreatic Cancer Research

ResearcherWakayama Medical UniversityActive in the last 2 years

Yasunobu Yamashita

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6725-5708; OpenAlex author ID A5034875050. Sources: OpenAlex.

Their work

Papers
18 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 3 papers · 2020: 2 papers · 2021: 4 papers · 2022: 3 papers · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 3 papers

Papers 18

  1. Comparison of Nanoliposomal Irinotecan Plus Fluorouracil/Leucovorin and S-1, Irinotecan, and Oxaliplatin as Second-Line Chemotherapy After Gemcitabine Plus Nab… Co-author DOI 10.1002/jhbp.70122↗
  2. Reply to "Prognostic value of functional assessment in sarcopenia among pancreatic cancer patients". Co-author DOI 10.1007/s00535-026-02446-w↗
  3. Contrast-enhanced harmonic endoscopic ultrasonography (EUS)-guided tissue acquisition significantly improves diagnostic yield for small liver metastases derive… Co-author DOI 10.1016/j.pan.2025.12.001↗
  4. Impact of sarcopenia and changes in skeletal muscle mass on prognosis of patients with pancreatic ductal adenocarcinoma receiving chemotherapy with first-line … Co-author DOI 10.1007/s00535-025-02283-3↗
  5. Utility of contrast-enhanced harmonic endoscopic ultrasonography for prediction of pathological response after neoadjuvant chemotherapy in patients with pancre… Co-author DOI 10.1016/j.pan.2023.10.016↗
  6. Impact of sarcopenia on prediction of progression-free survival and overall survival of patients with pancreatic ductal adenocarcinoma receiving first-line gem… Co-author DOI 10.1016/j.pan.2021.12.013↗
  7. Contrast-enhanced harmonic endoscopic ultrasonography for predicting the efficacy of first-line gemcitabine and nab-paclitaxel chemotherapy in pancreatic cance… Co-author DOI 10.1016/j.pan.2022.04.005↗
  8. Kras Gene Analysis Using Liquid-Based Cytology Specimens Predicts Therapeutic Responses and Prognosis in Patients with Pancreatic Cancer. Co-author DOI 10.3390/cancers14030551↗
  9. Computed tomography findings for predicting the future occurrence of pancreatic cancer: value of pancreatic volumetry. Co-author DOI 10.1007/s10147-021-01915-x↗
  10. Value of Low-Mechanical-Index Contrast-Enhanced Transabdominal Ultrasound for Diagnosis of Pancreatic Cancer: A Meta-analysis. Co-author DOI 10.1016/j.ultrasmedbio.2021.08.005↗
  11. Covered self-expandable metal stents versus plastic stents for preoperative biliary drainage in patient receiving neo-adjuvant chemotherapy for borderline rese… Co-author DOI 10.1111/den.13926↗
  12. Value of contrast-enhanced harmonic endoscopic ultrasound for diagnosing hepatic metastases of pancreatic cancer: A prospective study. Co-author DOI 10.1111/jgh.15661↗
  13. Fully covered self-expandable metal stent with an anti-migration system vs plastic stent for distal biliary obstruction caused by borderline resectable pancrea… Co-author DOI 10.1097/md.0000000000018718↗
  14. Utility of Contrast-Enhanced Harmonic Endoscopic Ultrasonography for Early Diagnosis of Small Pancreatic Cancer. Co-author DOI 10.3390/diagnostics10010023↗
  15. Impact of endoscopic ultrasonography on diagnosis of pancreatic cancer. Last author DOI 10.1007/s00535-018-1519-2↗
  16. Value of contrast-enhanced harmonic endoscopic ultrasonography with enhancement pattern for diagnosis of pancreatic cancer: A meta-analysis. Co-author DOI 10.1111/den.13290↗
  17. Endoscopic Ultrasound for Early Diagnosis of Pancreatic Cancer. First author DOI 10.3390/diagnostics9030081↗
  18. Tumor vessel depiction with contrast-enhanced endoscopic ultrasonography predicts efficacy of chemotherapy in pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e31827fe94c↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masayuki Kitano · 17 shared papers, 2019–2026 · strength 2.71
  2. Masahiro Itonaga · 15 shared papers, 2013–2026 · strength 2.34
  3. Takashi Tamura · 14 shared papers, 2019–2026 · strength 2.31
  4. Yuki Kawaji · 13 shared papers, 2020–2026 · strength 2.20
  5. Reiko Ashida · 12 shared papers, 2021–2026 · strength 2.14
  6. Tomoya Emori · 9 shared papers, 2021–2026 · strength 1.56
  7. Keiichi Hatamaru · 10 shared papers, 2019–2023 · strength 1.21
  8. Manabu Kawai · 9 shared papers, 2020–2023 · strength 1.09
  9. Hiroki Yamaue · 4 shared papers, 2020–2022 · strength 0.42
  10. Takeichi Yoshida · 4 shared papers, 2013–2020 · strength 0.40
  11. Ken‐ichi Okada · 3 shared papers, 2020–2021 · strength 0.30
  12. Seiko Hirono · 3 shared papers, 2020–2021 · strength 0.30
  13. Masatoshi Kudo · 2 shared papers, 2019–2021 · strength 0.24
  14. Yuji Kitahata · 2 shared papers, 2020–2021 · strength 0.21
  15. Motoki Miyazawa · 2 shared papers, 2020–2021 · strength 0.21
  16. Ken‐ichi Okada · 1 shared paper, 2023 · strength 0.17
  17. ChristophF Dietrich · 1 shared paper, 2021 · strength 0.13
  18. Atsushi Sofuni · 1 shared paper, 2021 · strength 0.13
  19. Mirko D’Onofrio · 1 shared paper, 2021 · strength 0.13
  20. Yoshiki Hirooka · 1 shared paper, 2021 · strength 0.13
  21. Bertrand Napoléon · 1 shared paper, 2019 · strength 0.11
  22. Pietro Fusaroli · 1 shared paper, 2019 · strength 0.11
  23. Rodica Gincul · 1 shared paper, 2019 · strength 0.11
  24. Jun Kato · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.